Literature DB >> 3533968

Expression of epidermal growth factor receptor and associated glycoprotein on cultured human brain tumor cells.

P A Steck, G E Gallick, S A Maxwell, W S Kloetzer, R B Arlinghaus, R P Moser, J U Gutterman, W K Yung.   

Abstract

The expression of epidermal growth factor (EGF-R) in normal glial and glioma cells grown in culture was examined by using several independent assays. Immunoprecipitation with the monoclonal antibody R1 of extracts from metabolically labeled glial and glioma cells revealed a protein of Mr approximately 170,000, with a migration in sodium dodecyl sulfate-polyacrylamide gels identical to the EGR-R of A431 epidermal carcinoma cells. Furthermore, in the majority of glioma extracts, a protein of Mr approximately 190,000 was specifically immunoprecipitated by this antibody. Similar results were obtained by immunoblotting with a second antibody directed against a synthetic peptide in the sequence of the v-erb-B oncogene. In cell lines expressing both proteins, each was specifically phosphorylated on tyrosine in immune complex kinase assays. The majority of glioma cells bound between 40,000 to 80,000 125I-labeled epidermal growth factor molecules per cell. These results suggest that the expression of EGF-R is common in cultured human glioma cells. In addition, a structurally related protein, is expressed in some of these cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3533968     DOI: 10.1002/jcb.240320102

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  9 in total

1.  Platelet-derived growth factor receptor independent proliferation of human glioblastoma cells: selective tyrosine kinase inhibitors lack antiproliferative activity.

Authors:  Dietmar Gross; Günther Bernhardt; Armin Buschauer
Journal:  J Cancer Res Clin Oncol       Date:  2006-05-31       Impact factor: 4.553

2.  Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients.

Authors:  David A Reardon; Charles A Conrad; Timothy Cloughesy; Michael D Prados; Henry S Friedman; Kenneth D Aldape; Paul Mischel; Jane Xia; Clifford DiLea; Jerry Huang; William Mietlowski; Margaret Dugan; Wei Chen; W K Alfred Yung
Journal:  Cancer Chemother Pharmacol       Date:  2012-03-07       Impact factor: 3.333

3.  Effects of 131I-EGF on cultured human glioma cells.

Authors:  J Capala; M Pråhl; S Scott-Robson; J Pontén; B Westermark; J Carlsson
Journal:  J Neurooncol       Date:  1990-12       Impact factor: 4.130

Review 4.  The autocrine loop of TGF-alpha/EGFR and brain tumors.

Authors:  P Tang; P A Steck; W K Yung
Journal:  J Neurooncol       Date:  1997-12       Impact factor: 4.130

5.  Epidermal growth factor receptor expression in human gliomas.

Authors:  S H Torp; E Helseth; A Dalen; G Unsgaard
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Amplified gene for the epidermal growth factor receptor in a human glioblastoma cell line encodes an enzymatically inactive protein.

Authors:  A Wells; J M Bishop; D Helmeste
Journal:  Mol Cell Biol       Date:  1988-10       Impact factor: 4.272

7.  Characterization of a continuous human glioma cell line DBTRG-05MG: growth kinetics, karyotype, receptor expression, and tumor suppressor gene analyses.

Authors:  C A Kruse; D H Mitchell; B K Kleinschmidt-DeMasters; W A Franklin; H G Morse; E B Spector; K O Lillehei
Journal:  In Vitro Cell Dev Biol       Date:  1992 Sep-Oct

8.  A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas.

Authors:  Phioanh Leia Nghiemphu; Albert Lai; Richard M Green; David A Reardon; Timothy Cloughesy
Journal:  J Neurooncol       Date:  2012-08-24       Impact factor: 4.130

9.  Receptor expression, cytogenetic, and molecular analysis of six continuous human glioma cell lines.

Authors:  C A Kruse; M Varella-Garcia; B K Kleinschmidt-Demasters; G C Owens; E B Spector; H Fakhrai; E Savelieva; B C Liang
Journal:  In Vitro Cell Dev Biol Anim       Date:  1998-06       Impact factor: 2.723

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.